Phosphagenics reports pain relief
Monday, 08 December, 2008
Phosphagenics has completed a Phase I trial for its drug delivery system TPM to deliver lidocaine topically.
The trial, to assess the bioavailability, safety and tolerability of the application, found the formulation was able to deliver more of the pain relief drug to the skin compared to a leading commercial product, Xylocaine, marketed by AstraZeneca.
The open label, single centre study was conducted at the Centre for Pharmaceutical Research at the University of South Australia in 11 healthy adult volunteers.
TPM is being trialled in a number of small molecule delivery applications, including hormones, morphine and oxycodone. It is also being expanded to large molecule applications, such as peptides.
The company’s lead product is Phospha E, a vitamin E derivative it is exploring as a neutraceutical.
NSW Govt delivers foot-and-mouth vaccine to protect livestock
A biodegradable vaccine to protect livestock from foot-and-mouth disease has been developed as...
Scientists optimise delivery of mRNA to target cells
A highly versatile new method captures and attaches antibodies to the surface of mRNA-loaded...
'Anti-reward' brain network helps explain cocaine addiction
A new study identifies a specific 'anti-reward' network deep in the brain that undergoes...
